When Plateaus Typically Occur on Mounjaro

A weight plateau usually means progress has slowed or stabilised after an earlier period of weight loss, not that treatment has suddenly stopped working. During the first months on Mounjaro, many patients are still moving through dose escalation, adjusting to appetite changes, and building a more stable treatment routine, so this is not always the stage when a true plateau appears. In Singapore, Mounjaro (tirzepatide) is a prescription-only medicine used under doctor supervision. To learn more about the broader early-treatment journey, readers can also explore What to Expect During Your First Months on Mounjaro Under Medical Supervision.

Key Takeaways

• A true plateau on Mounjaro usually does not happen in the first few weeks, because treatment starts at 2.5 mg once weekly for 4 weeks and then steps up to 5 mg, with further increases only after at least 4 weeks on the current dose.

• In a 2025 post-hoc analysis of SURMOUNT-1 and SURMOUNT-4, most participants reached a weight plateau by week 72, not during the earliest treatment phase.

• The same analysis reported median time to weight plateau in SURMOUNT-1 of about 24.3 weeks in participants with overweight, 26.0 weeks in class I obesity, and 36.1 weeks in class II and III obesity.

• ECO 2025 reporting on long-term tirzepatide data summarised that most participants reached a weight-loss plateau in the first 6 to 12 months and then largely maintained results.

• In Singapore, Mounjaro is approved for weight management as an adjunct to a reduced-calorie diet and increased physical activity, so plateaus are interpreted within a broader treatment plan rather than by the scale alone.

Why plateaus should be understood carefully

A plateau is often misunderstood as a sign that treatment has failed. Clinically, it usually means the earlier phase of weight reduction has slowed and body weight is becoming more stable. That can happen in many weight-management approaches and is not unique to tirzepatide. The more useful question is when that slowing tends to happen and whether it fits the expected treatment course. This interpretation is supported by recent tirzepatide plateau analyses and longer-term trial follow-up.

That distinction matters in early treatment. A patient who has only recently started Mounjaro is usually still in the initiation or dose-adjustment period, so a brief slowdown in the first month or two is not always the same as a true long-term plateau. This is an inference from the dosing schedule and the longer time-to-plateau data.

When plateaus typically occur on Mounjaro

Usually not in the first month

Current EMA product information starts tirzepatide at 2.5 mg once weekly for 4 weeks, then increases to 5 mg once weekly. If needed, later increases are made in 2.5 mg increments after at least 4 weeks on the current dose.

That means the first month is mainly an initiation phase, not usually the stage when doctors expect a durable plateau. Most patients are still entering active treatment rather than having fully expressed the longer-term weight response. This is an inference from the stepwise dosing framework.

Plateaus are more often seen later, after early dose escalation

The strongest recent signal comes from the 2025 post-hoc analysis of SURMOUNT-1 and SURMOUNT-4. It found that most participants reached a weight plateau by week 72, and the median time to plateau in SURMOUNT-1 varied by baseline BMI category, from about 24 to 36 weeks.

In practical terms, that suggests many plateaus tend to emerge months into treatment, not immediately after starting. A rough expectation from the published analysis is that some patients may begin to plateau around 6 months, while others may continue losing for longer before the curve flattens. That sentence is an inference from the reported median times to plateau.

A broad rule of thumb is often 6 to 12 months

A 2025 European Association for the Study of Obesity summary of long-term tirzepatide data reported that most participants reached a weight-loss plateau in the first 6 to 12 months and then largely maintained their results over time.

This wider time window fits the more detailed plateau analysis reasonably well. It also matches the idea that patients often continue to see movement beyond the first few months, especially while dose escalation is still underway or later doses are still being tolerated and adjusted. The second sentence is an inference from the EASO summary and the EMA dosing schedule.

Why the first months often do not represent a true plateau

During the first months, many patients are still moving through 2.5 mg, 5 mg, and possibly later dose steps. EMA product information also lists 5 mg, 10 mg, and 15 mg as recommended maintenance doses for adults, which means early treatment is often still a period of finding the appropriate maintenance level.

Because of that, weight change in the first two or three months can still be evolving. Appetite, fullness, meal size, and gastrointestinal tolerability may all still be shifting, so a short slowdown during this period is not automatically a stable plateau. This is an inference from the titration schedule and the product information’s appetite and tolerability framework.

What influences when a plateau happens

The 2025 plateau analysis found that higher tirzepatide doses, younger age, and female sex were associated with a longer time to weight plateau.

That does not mean doctors can predict exactly when one individual patient will plateau. It does mean the timing is variable, and some patients may continue losing for longer than others before weight stabilises. This is a direct inference from the reported associations.

Baseline BMI may matter too. In the same analysis, the median time to plateau was shorter in participants with overweight and class I obesity than in those with class II or III obesity.

Why plateau timing should not be confused with treatment failure

A plateau can still be compatible with treatment benefit. HSA’s Singapore indication explicitly includes both weight loss and weight maintenance, which means a period of stabilisation can still fit the approved treatment concept rather than contradict it.

Longer-term tirzepatide trial data also support this view. In SURMOUNT-1, tirzepatide produced substantial weight reduction over 72 weeks, and in SURMOUNT-4, continuation helped maintain and augment prior loss rather than simply causing indefinite linear decline forever.

So the clinically useful question is often not “Has weight loss stopped completely?” but “Has the patient reached a more stable phase, and is that phase being maintained safely?” That is an inference from the maintenance framing in HSA’s indication and the longer-term trial results.

What doctors usually look at when progress slows

When weight loss slows, doctors usually review the broader treatment context rather than the scale alone. In Singapore, Mounjaro is used as an adjunct to a reduced-calorie diet and increased physical activity, so the review often includes dose stage, tolerability, appetite change, food intake, hydration, and whether treatment has reached a more stable maintenance rhythm. This is an inference from HSA’s indication and the EMA titration framework.

This matters because a slowdown at month 2 or 3 is different from a plateau emerging after 6 to 12 months of more established treatment. The first may reflect normal early variability; the second may reflect a more typical weight-stabilisation phase. This is an inference from the plateau timing data.

What patients may notice before a plateau

Before a plateau, patients often still notice changing appetite, portion size, or meal frequency, even if week-to-week scale movement becomes less dramatic. EMA product information describes tirzepatide as reducing energy intake and appetite by increasing satiety and fullness and decreasing hunger.

That means progress can still be clinically meaningful even if it becomes less linear. A flatter curve does not always mean no effect; sometimes it means treatment is moving from active reduction toward a more stable maintenance pattern. This is an inference supported by the appetite effects and long-term plateau data.

Takeaway

So, when do plateaus typically occur on Mounjaro? Current evidence suggests they usually happen later than the first few months. In a recent tirzepatide analysis, most participants reached a plateau by week 72, with median time to plateau in SURMOUNT-1 ranging from about 24 to 36 weeks depending on baseline BMI, while broader 2025 reporting summarised that many plateaus occur in the first 6 to 12 months. In Singapore, that timing should be interpreted within a prescription-only, doctor-supervised treatment plan where Mounjaro is used alongside diet and physical activity, and where a plateau may still fit the broader goal of weight maintenance rather than signal failure.

FAQ

Do plateaus usually happen in the first month on Mounjaro?

Not typically. The first month is generally the 2.5 mg initiation phase, so many patients are still starting treatment rather than reaching a true long-term plateau.

When do many patients start to plateau?

Recent analyses suggest many patients plateau months into treatment, often around the 6- to 12-month range, though individual timing varies.

Can some patients plateau later than others?

Yes. Higher tirzepatide doses, younger age, and female sex were associated with a longer time to plateau in a 2025 analysis.

Does a plateau mean Mounjaro has stopped working?

Not necessarily. HSA’s Singapore indication includes weight maintenance as part of treatment, so stabilisation can still fit the treatment goal.

Is Mounjaro used on its own in Singapore?

No. HSA states that for weight management it is used as an adjunct to a reduced-calorie diet and increased physical activity in eligible adults.